Introduction
============

Tumors of the small bowel are rare. The small bowel accounts for 75 % of the length and over 90 % of the mucosal surface of the gastrointestinal tract; however, small bowel cancers represent only 1 % to 3 % of all primary gastrointestinal malignancies [@JR704-1] [@JR704-2] [@JR704-3] . The clinical presentation of small bowel cancers is nonspecific with diarrhoea, abdominal pain, bleeding, extraintestinal symptoms (such as paraneoplastic phenomena) or acute small bowel obstruction [@JR704-4] . Diagnosis of small bowel tumors is often delayed [@JR704-5] [@OR704-6] , partly due to the fact that they are usually asymptomatic at the early stage [@JR704-7] and there is low clinical suspicion. By the time a diagnosis is reached, approximately 50 % of small bowel cancers have already metastasised [@JR704-8] .

Nowadays, capsule endoscopy (CE) is a widely-accessible and minimally invasive mode for diagnostic investigation of the small bowel [@JR704-9] . CE also gives detailed and panoramic views of the entire small bowel, therefore it is suitable as first line in the diagnostic workup of small bowel tumors. Since its introduction into clinical practice, the literature on small bowel cancer diagnosis by CE remains limited [@JR704-10] . This study aims to describe the frequency, indications and diagnostic work-up of patients with small bowel malignancy found by CE at a tertiary referral center in Scotland for small bowel capsule endoscopy (SBCE).

Patients and methods
====================

This retrospective study involved all patients who underwent SBCE between March 2005 and October 2015 at the Centre for Liver and Digestive Disorders, Royal Infirmary of Edinburgh, Scotland. Patients excluded from CE were those with known small bowel obstruction, implanted cardiac pacemakers and/or pregnancy. Patients with risk factors for capsule retention, such as those with a high probability of small bowel stenotic lesion or known small bowel inflammation (e. g. Crohn's disease) underwent CE provided there were no obstructive symptoms. The standard protocol for performing CE involved a 12-hour fast before the procedure, with intake of 2 liters of bowel preparation solution (polyethylene glycol (PEG) before 2013, and sodium picosulphate from 2013). Patients underwent CE using one of two capsule models; either PillCam ^TM^ SB (Medtronic, USA) or MiroCam ^TM^ (IntroMedic, Seoul, Korea). At our center, all CEs are reported by at least 1 of 3 experienced CE readers (experience with \> 100 CEs before the start of this study).

The data were collected from a prospectively-designed database of all patients undergoing SBCE at our center. Patient notes from the centralized patient management platform for our healthcare trust were searched to determine those in whom a small bowel malignancy was confirmed. Further data were then gathered on previous and subsequent diagnostic investigations, management and outcome for these patients.

Data gathered: age, gender, indication for SBCE, SBCE findings, cross-sectional/radiological imaging both before and after SBCE, subsequent clinical outcomes. Iron deficiency anemia (IDA) was defined as per World Health Organisation guidelines: Hb \< 13 g/dL in males or \< 12 g/dL in females, with evidence of iron deficiency (MCV \< 80 fL or ferritin \< 12 -- 15 µg/L).

A literature review of the databases PubMed and Embase was also conducted for publications reporting the epidemiology of small bowel tumors. This was carried out via a focused search using the terms "small bowel tumors" and "small bowel malignancy" as keywords. Relevant studies were included if they reported the incidence of small bowel tumors in their cohorts.

Results
=======

The total number of SBCE studies carried out between 2005 and 2015 was 1949; 1082 performed with PillCam ^TM^ SB and 867 using MiroCam ^TM^ . Small bowel malignancy was confirmed in 7 patients (0.36 %; 5 male/2 female). The median age was 50 years (range 34 -- 67). There were 2 lymphomas, 2 gastrointestinal stromal tumors (GISTs), 2 duodenal adenocarcinomas and 1 jejunal metastasis from a sarcoma of the lung. In this subgroup, indications for CE were IDA (iron-deficiency anemia) (n = 5), unexplained diarrhoea (n = 1) and clinical suspicion of lymphoma (n = 1). The median time from first symptom to diagnosis in our patients was 12 months (range 2 -- 18). All patients with a small bowel malignancy had other investigations carried out prior to SBCE. Six of 7 had prior negative bidirectional gastrointestinal endoscopy. In 2 patients, SBCE was carried out immediately following negative UGIE and colonoscopy. One patient had a normal upper gastrointestinal endoscopy (UGIE) with no colonoscopy carried out. Other prior investigations before SBCE included: abdominal ultrasound scan (USS) (n = 2), computed tomography (CT) imaging of the chest, abdomen and/or pelvis (n = 4), small bowel barium follow-through (n = 1) and bone marrow aspirate (n = 1). The mean number of diagnostic procedures per patient, before CE, was 3. All prior diagnostic procedures were normal or nondiagnostic. Two of the 7 patients experienced asymptomatic capsule retention. Both these patients had duodenal adenocarcinomas; 1 required capsule removal by push enteroscopy and the other by UGIE.

All 7 patients had further investigations following CE. Six had a CT scan of their chest, abdomen, and pelvis carried out for staging. Two patients had push enteroscopy (PE), both of whom had a diagnosis of duodenal adenocarcinoma. One had double balloon enteroscopy (DBE), 2 had colonoscopy, 2 had UGIE; and there was 1 bone marrow aspiration. All patients had histological confirmation of malignancy. The SBCE findings (and subsequent investigations) led to a change in management in all our patients diagnosed with a small bowel malignancy. Three subjects had a small bowel resection. One patient with a GIST was also administered Imatinib following resection. Of the 2 individuals with a duodenal adenocarcinoma, 1 underwent a gastroenterostomy and 1 had an elective Whipple procedure. Four patients died within 1 year of their diagnosis, 2 of whom died after surgery and the other 2 before their planned surgery. Of the 3 surviving patients at the time of writing, 2 are being followed up by the oncology team and one by the gastroenterology team.   [Table 1](#TB704-1){ref-type="table"} summarizes the findings.

###### Case-based demographics, clinical findings, investigations, management, and outcomes in 7 Patients with small bowel tumor diagnosis

  -------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  **Patient Number**   **Indication**      **Time from presentation to diagnosis**   **Diagnosis and CE appearances**                                                                            **Previous Investigations**                             **Subsequent Investigations**    **Mode used to confirm diagnosis and findings**                                                          **Management**                              **Outcome**
  -------------------- ------------------- ----------------------------------------- ----------------------------------------------------------------------------------------------------------- ------------------------------------------------------- -------------------------------- -------------------------------------------------------------------------------------------------------- ------------------------------------------- ----------------------------
  1                    IDA                 2 months                                  Duodenal adenocarcinoma:\                                                                                   Abdominal USS, UGIE, colonoscopy                        UGIE, PE, CT CAP                 UGIE:\                                                                                                   Gastroenterostomy and palliative care       Deceased
                                                                                     Stricturing, nodular mucosa, CE retained                                                                                                                                                             Tumor in duodenum and retained CE                                                                                                                    

  2                    IDA                 18 months                                 GIST (right iliac fossa):\                                                                                  CT, UGIE, colonoscopy                                   CT CAP                           CT CAP:\                                                                                                 Small bowel resection                       GI follow-up
                                                                                     Mucosal bulge                                                                                                                                                                                        Soft tissue nodules with flecks of calcification                                                                                                     

  3                    IDA                 2 months                                  Jejunal metastasis from sarcoma of lung:\                                                                   CT chest, BMA, UGIE                                     DBE, CT CAP                      DBE:\                                                                                                    Small bowel resection and palliative care   Deceased
                                                                                     Multiple infiltrative lesions                                                                                                                                                                        Area of intussusception with jejunal lesions                                                                                                         

  4                    Possible lymphoma   11 months                                 Lymphoma\                                                                                                   Small bowel follow through, UGIE, colonoscopy, CT CAP   Colonoscopy                      Colonoscopy:\                                                                                            Planned surgery                             Deceased\
                                                                                     (diffuse):\                                                                                                                                                                                          Extensive pseudopolyp formation                                                                                                                      (3 months after diagnosis)
                                                                                     Extensive pseudopolyp formation at terminal ileum                                                                                                                                                                                                                                                                                                         

  5                    IDA                 13 months                                 Duodenal adenocarcinoma:\                                                                                   UGIE, colonoscopy, abdominal USS, CT                    PE, CT CAP                       PE:\                                                                                                     Elective Whipple procedure                  Oncology follow-up
                                                                                     Capacious duodenum, obstructing lesion with infiltrative characteristics in proximal jejunum, CE retained                                                                                            Tumor in duodenum and retained CE                                                                                                                    

  6                    IDA                 16 months                                 GIST (jejunal):\                                                                                            UGIE, colonoscopy                                       CT CAP                           CT CAP:\                                                                                                 Small bowel resection and imatinib          Oncology follow-up
                                                                                     Mucosal bulge                                                                                                                                                                                        Area of mucosal thickening and inflammatory changes at duodenal-jejunal junction, reactive lymph nodes                                               

  7                    Diarrhoea           unknown                                   Lymphoma\                                                                                                   UGIE, colonoscopy                                       UGIE, colonoscopy, CT CAP, BMA   UGIE:\                                                                                                   Planned surgery                             Deceased\
                                                                                     (diffuse):\                                                                                                                                                                                          Severe rugal hyperplasia                                                                                                                             (2 months after diagnosis)
                                                                                     Infiltrative appearances                                                                                                                                                                                                                                                                                                                                  
  -------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

BMA, bone marrow aspiration; CE, capsule endoscopy; CT CAP, computed tomography of chest, abdomen and pelvis; IDA, iron deficiency anaemia; PE, push enteroscopy; UGIE, upper gastrointestinal endoscopy; USS, ultrasound scan

Discussion
==========

Introduction of wireless CE into clinical practice has radically changed diagnostic algorithms for small bowel pathology [@JR704-9] [@JR704-11] . However, there is a growing body of evidence suggesting a high miss rate for sinister small bowel pathology using CE [@JR704-12] [@JR704-13] [@JR704-14] [@JR704-15] . Radiological modalities, such as small bowel follow-through, enteroclysis and cross-sectional imaging (CT and magnetic resonance imaging), permit detection of lesions in the whole small bowel but provide inadequate detail of the bowel lumen and mucosa [@JR704-16] . In our cohort, our patients underwent a similar number of investigations preceding SBCE compared to other studies (range 3.19 -- 4.6) (See [Table 2](#TB704-2){ref-type="table"} for a comparison of previous studies on SB malignancy diagnosed by CE) [@JR704-17] [@JR704-18] [@JR704-19] [@JR704-20] [@JR704-21] [@JR704-22] [@JR704-23] [@JR704-24] [@JR704-25] [@JR704-26] [@JR704-27] [@JR704-28] [@JR704-29] [@JR704-30] [@JR704-31] [@JR704-32] [@JR704-33] [@JR704-34] [@JR704-35] [@JR704-36] [@JR704-37] [@JR704-38] [@JR704-39] [@JR704-40] [@JR704-41] [@JR704-42] [@JR704-43] .

###### Summary of previously published studies on SB tumors diagnosed by CE.

  -------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  **Authors, Year \[ref\]**                **Country**   **Single/**\   **Prospective/**\   **No. of pts**   **Average no. of Ix before CE**   **Capsule retention (%)**   **Pts with SB tumors (%)**   **Benign SB tumors**   **Malignant SB tumors**   **AdenoCA**   **Carcinoid**   **GIST**   **Lymphoma**   **Metastases**
                                                         **Multi-**\    **Retrospective**                                                                                                                                                                                                                        
                                                         **Centre**                                                                                                                                                                                                                                              
  ---------------------------------------- ------------- -------------- ------------------- ---------------- --------------------------------- --------------------------- ---------------------------- ---------------------- ------------------------- ------------- --------------- ---------- -------------- ----------------
  Caunedo et al, 2004 [@JR704-17]          Spain         Single         Retrospective         88             3                                 1 (1.1 %)                     6 (6.8)                    NS                     NS                        --                                                      

  Delvaux et al, 2004 [@JR704-18]          France        Single         Prospective           44             NS                                NS                           10 (22 %)                    9                       1                        1            --              --         --             --

  Rastogi et al, 2004 [@JR704-19]          USA           Single         Retrospective         43             6.11                               1 (2.3 %)                    1 (2.3 %)                   0                       1                       --            --              --         --              1

  Carlo et al, 2005 [@JR704-20]            USA           Single         Retrospective        652             NS                                12 (1.8 %)                   37 (5.3 %)                  NS                     NS                        --                                                      

  Teramoto et al, 2005 [@JR704-21]         Mexico        Single         Retrospective         45             NS                                NS                            2 (4.4 %)                  NS                     NS                        --                                                      

  Bailey et al, 2006 [@JR704-22]           Australia     Multi          Prospective          416             3.42                               3 (0.7 %)                   26 (6.3 %)                   9                      18                        5             6               3          1              3

  Cobrin et al, 2006 [@JR704-23]           Italy         Single         Retrospective        562             4.44                              NS                           35 (6.2 %)                  10                      25                        9            10              --          5             --

  Urbain et al, 2006 [@JR704-24]           Belgium       Multi          Retrospective        443             3.6                               NS                           11 (2.4 %)                   0                      11                        4             1               2          3             --

  van Tuyl et al, 2006 [@JR704-25]         Netherlands   Single         Retrospective        250             NS                                 2 (0.8 %)                    7 (3 %)                    NS                     NS                        --                                                      

  Baichi et al, 2007 [@JR704-26]           USA           Single         Retrospective        300             0.024                              2 (0.7 %)                    9 (3 %)                     2                       8                        4            --               2         --             --

  Estévez et al, 2007 [@JR704-27]          Spain         Single         Retrospective        320             NS                                NS                           23 (7.18 %)                  2                      13                        3             1               6          3             --

  Schwartz et al, 2007 [@JR704-28]         USA           Multi          Retrospective       NS               4.6                               NS                           86                          35                      52                       18            17               3          4              1

  Rondonotti et al, 2008 [@JR704-10]       Europe        Multi          Retrospective       5129             2.82                              12 (9.7 %)                  124 (2.4 %)                  16                     108                       23            17              36         12             12

  Spada et al, 2008 [@JR704-29]            Italy         Single         Retrospective        380             5                                  3 (0.8 %)                   13 (3.4 %)                   0                      13                        1             3               2          3              4

  Ersoy et al, 2009 [@JR704-30]            Turkey        Single         Retrospective         66             3                                 NS                            4 (6 %)                     0                       4                        1            --               1          1             --

  Ren et al, 2009 [@JR704-31]              China         Single         Retrospective        155             NS                                NS                            9 (5.8 %)                  NS                     NS                                                                                

  Cheung et al, 2010 [@JR704-32]           Korea         Multi          Retrospective       1332             3.19                              1 (0.08 %)                  57 (4.3 %)                   24                     33                         3            --              20         8              2

  Sanhueza et al, 2010 [@JR704-33]         Chile         Single         Retrospective         69             NS                                NS                           3 ( 4.3 %)                  NS                     NS                        --                                                      

  Sîngeap et al, 2010 [@JR704-34]          Moldova       Single         Retrospective        102             NS                                0                            5 (4.9 %)                   NS                     NS                        --                                                      

  Trifan et al, 2010 [@JR704-35]           Romania       Single         Retrospective        102             3                                 NS                           5 (4.9 %)                    0                      5                         1            1                3         --             --

  Sidhu et al, 2011 [@JR704-36]            UK            Single         Retrospective       1600             4.7                               4 (16.6 %)                  24 ( 1.5)                     8                     16                         4            2                5         4              1

  Achour et al, 2012 [@JR704-37]           Morocco       Single         Retrospective         95             3.7                               0                           13 (13.6 %)                   0                     13                         2            2                9         --             --

  Urgesi et al, 2012 [@JR704-38]           Italy         Single         Retrospective        500             NS                                NS                          20 (4 %)                     NS                     NS                        --            --               9         --             --

  Zhang et al, 2012 [@JR704-39]            China         Single         Prospective          385             2                                 7 (1.8 %)                   59 (15.3 %)                   9                     34                         1            --              27         4              2

  Pongprasobchai et al, 2013 [@JR704-40]   Thailand      Single         Retrospective        103             NS                                1 (1 %)                      7 (13 %)                    NS                     NS                        --                                                      

  Zagorowicz et al, 2013 [@JR704-15]       Poland        Single         Retrospective        145             NS                                NS                          15 (10 %)                     9                      6                         2            --               3         --             1

  Yang et al, 2014 [@JR704-41]             China         Single         Retrospective        243             4                                 2 (0.8 %)                    2 (0.82 %)                   0                      2                         1            --               1         --             --

  Calabrese et al, 2015 [@JR704-42]        Italy         Single         Retrospective        849             NS                                4 (5.3 %)                   55 (6.5 %)                   27                     28                        14            --               9         5              --

  Moneghini et al, 2016 [@JR704-43]        Italy         Single         Retrospective        606             NS                                1 (5.9 %)                   17 (2.8 %)                    0                     17                         7            5                5         --             --

  Johnston et al, 2016 (this study)        UK            Single         Retrospective       1949             3                                 NS                           7 (0.36 %)                   0                      7                         2            --               2         2              1
  -------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

AdenoCA, adenocarcinoma; CE, capsule endoscopy; GIST, gastrointestinal stromal tumor; Ix, investigations; NS, not specified; pts, patients; SB, small bowel

The reported rate of small bowel malignancy diagnosis by CE varies. Our cohort has a very low reported frequency of small bowel malignancy diagnosis at 0.36 %. Our results are consistent with other published studies on the detection of SB malignancies by CE, detailed in [Table 2](#TB704-2){ref-type="table"} . Notably, in a large multicenter study by Rondonotti et al with 5129 CEs from 29 centers in 10 European countries, the authors observed a significant inverse correlation between the frequency of tumors diagnosed and the number of CE examinations performed at a particular center [@JR704-10] . In contrast, this single-center study originated at a tertiary hospital serving a large but relatively homogeneous population from southeast Scotland. Furthermore, the lower incidence of small bowel malignancy found on CE in our group may also, to some extent, be an artifact of less stringent local CE referral policies due to the accessibility of the CE service. This is reflected by the overall high proportion of normal CEs (971/1949; 49.8 %). A significant 51.0 % (994/1949) of our referrals were for obscure gastrointestinal bleeding and 41.3 % (805 /1949) specifically for IDA; the low diagnostic yield is in line with that of previous published studies and systematic reviews on CE in patients with IDA [@JR704-44] .

With 1949 CE reports, our study represents one of the largest single-center studies to date reporting on small bowel malignancies.   [Fig.1](#FI704-1){ref-type="fig"} shows the forest plot for the rate of small bowel tumors detected by CE in the studies from [Table 2](#TB704-2){ref-type="table"} : using the random effects model (DerSimonian-Laird) due to high study heterogeneity, the overall proportion of small bowel tumors diagnosed on CE was 0.05 (95 %CI 0.04 -- 0.06), i. e. 5 %. When only malignant tumors (if specified by the respective studies) were taken into account, the rate of diagnosis via CE was 0.03 (95 %CI 0.02 -- 0.04), or 3 %, [Fig. 2](#FI704-2){ref-type="fig"} .
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The most common indication for CE in our study was IDA (71.4 %). This matches the published reports on small bowel cancers diagnosed through CE, where IDA accounted for 60 % to 100 % of indications. In our group, malignancy was diagnosed more frequently in younger patients ( ≤ 55y) with IDA (3 of 312 CE cases, 0.96 %) compared with those older than age 55 years (2 of 682 CE cases, 0.29 %). Our findings highlight the importance of keeping small bowel malignancy on the differential diagnosis in younger patients with IDA [@JR704-44] [@JR704-45] .

Early detection of small bowel malignancy has a positive impact on survival. Overall, the prognosis of small bowel tumors remains poor [@JR704-46] [@JR704-47] [@JR704-48] and a diagnostic delay of up to 1.5 years has been estimated for malignant small bowel tumors. Features of small bowel tumors contributing to delayed diagnosis include their slow, extraluminal growth and lack of specific symptoms [@JR704-10] .

The major limitations of this observational study are its retrospective design and the fact that information on follow-up was only available for a limited number of patients in our cohort. This was due to the large catchment area of our tertiary referral center, which meant that a significant proportion of patients were returned to the care of their referring centers following CE. However, it still represents one of the largest studies to date on small bowel cancers diagnosed by CE.

Conclusion
==========

In summary, in our tertiary care center, the rate of diagnosis of small bowel malignancies via CE was 0.36 %. This was a low diagnostic yield in comparison to other studies, but possibly a truer figure given our large sample size from a single center. Younger patients referred for CE with IDA were more likely to be diagnosed with small bowel cancer. The mortality rate for patients diagnosed this way was high, with a 5-year survival rate of only 42.9 %. The potential diagnostic superiority of CE over other small bowel investigations and the resultant change in management plans suggest that CE is an invaluable third-line diagnostic procedure following negative bidirectional gastrointestinal endoscopy when other imaging modalities have failed.
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